Nitinotes Adds Weill Cornell to Pivotal EndoZip Obesity Trial

The clinical activation of Weill Cornell Medicine serves as a critical step for Nitinotes as it gathers data for future U.S. Food and Drug Administration marketing submissions. The EASE study functions as a prospective, randomized, two-arm blinded trial aimed at proving the safety and efficacy of the EndoZip platform. By utilizing automated suturing, the company seeks to move beyond manual endoscopic techniques, providing a more reproducible method for weight-loss interventions.

Lloyd Diamond, CEO of Nitinotes, noted that partnering with top-tier academic institutions is essential for building the clinical evidence required for broader adoption. Dr. Sharaiha, who directs endoscopy at the center and sits on the Nitinotes Scientific Advisory Board, emphasized that the shift toward minimally invasive options is driven by the urgent need to address obesity through accessible, effective medical care. While the EndoZip system already holds a CE Mark for use in European markets, it remains restricted to investigational use within the United States until the trial reaches its conclusion.